Skip to main content
Clinical Trials/ACTRN12612000757819
ACTRN12612000757819
Not yet recruiting
Phase 4

In patients undergoing thyroidectomy, which is more effective for the prevention of postoperative nausea and vomiting among ramosetron, low dose midazolam, and their combination?

Astellas pharma korea, INC.0 sites69 target enrollmentJuly 16, 2012

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
postoperative nausea and vomiting in patients undergoing thyroidectomy
Sponsor
Astellas pharma korea, INC.
Enrollment
69
Status
Not yet recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 16, 2012
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • patients undergoing thyroidectimy

Exclusion Criteria

  • severe impairment of bowel motility, insulin\-dependent diabetes mellitus, pregnancy or breast feeding, administration of antiemetic medication within 24 h before operation, history of cardiovascular or respiratory disease, active alcohol or drug usage, obesity (body mass index \> 35 kg/m2\), impaired renal and/or hepatic function

Outcomes

Primary Outcomes

Not specified

Similar Trials